Pharma Focus Asia

Johnson & Johnson Discovered First-of-its-kind RYBREVANT® for the Treatment of Patients with Non-Small Cell Lung Cancer

Johnson & Johnson has introduced RYBREVANT® (amivantamab-vmjw) as a groundbreaking therapy for the initial treatment of individuals diagnosed with non-small cell lung cancer (NSCLC) harbouring EGFR exon 20 insertion mutations. 

RYBREVANT® is a fully-human bispecific antibody that targets EGFR and MET, featuring immune cell-directing capabilities. It has gained approval in various markets, including the U.S. and Europe, as a monotherapy for adult patients with locally advanced or metastatic NSCLC possessing EGFR exon 20 insertion mutations, as identified by an FDA-endorsed test. 

This approval follows positive results from the Phase 3 PAPILLON study, which showcased RYBREVANT® in combination with chemotherapy substantially reducing the risk of disease progression or mortality by 61 percent compared to chemotherapy alone in previously untreated NSCLC patients with EGFR exon 20 insertion mutations. 

NSCLC accounts for the majority of lung cancer cases worldwide, with EGFR alterations being the most common actionable driver mutations. 

Clinical evidence indicates that patients with EGFR exon 20 insertion mutations typically derive limited benefits from existing third-generation EGFR tyrosine kinase inhibitors and chemotherapy. 

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024